European Medicines Agency Approves Use of Injections for Preventing AIDS
July 26, 202572 ViewsRead Time: 1 minutes
Font Size
16
The European Medicines Agency recommended on Friday approving the use of injections administered twice a year to prevent Human Immunodeficiency Virus (HIV), which scientists say can help stop the virus transmission.
HIV is a virus that attacks the body's immune system and weakens it. If left untreated, it can lead to Acquired Immunodeficiency Syndrome (AIDS), the most advanced stage of the disease.
The European Union's drug regulatory agency said in a statement that their evaluations of the drug (Lenacapavir) sold in Europe by Gilead Sciences under the brand name (Yescarta) showed that the drug is highly effective and is considered a major public health interest.
Once the European Commission approves the agency's guidelines, the drug will be allowed for use in all 27 EU countries.
Studies conducted last year indicated that Lenacapavir, which has already been used to treat people with HIV, is 100% effective in stopping infection in both women and men.
HIV is a virus that attacks the body's immune system and weakens it. If left untreated, it can lead to Acquired Immunodeficiency Syndrome (AIDS), the most advanced stage of the disease.
The European Union's drug regulatory agency said in a statement that their evaluations of the drug (Lenacapavir) sold in Europe by Gilead Sciences under the brand name (Yescarta) showed that the drug is highly effective and is considered a major public health interest.
Once the European Commission approves the agency's guidelines, the drug will be allowed for use in all 27 EU countries.
Studies conducted last year indicated that Lenacapavir, which has already been used to treat people with HIV, is 100% effective in stopping infection in both women and men.
